CO6561817A2 - Derivados de piridina di-sustituida como agentes anticancer - Google Patents
Derivados de piridina di-sustituida como agentes anticancerInfo
- Publication number
- CO6561817A2 CO6561817A2 CO12121461A CO12121461A CO6561817A2 CO 6561817 A2 CO6561817 A2 CO 6561817A2 CO 12121461 A CO12121461 A CO 12121461A CO 12121461 A CO12121461 A CO 12121461A CO 6561817 A2 CO6561817 A2 CO 6561817A2
- Authority
- CO
- Colombia
- Prior art keywords
- phenylene
- lower alkylene
- optionally substituted
- piridina
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un nuevo compuesto que tiene excelente efecto antitumoral. El compuesto de la presente invención se representa por lasiguiente fórmula general (1) en donde R1 y R2 son arilo o similar; A es alquileno inferior, el anillo X es arileno opcionalmente sustituido, E es un enlace o alquenileno inferior; el anillo Y es heterocicloalquileno opcionalmente sustituido que contiene uno o más átomos de nitrógeno, uno de los cuales está unido al grupo carbonilo adyacente; G es -NR-G2-, -N (alquilo inferior) -G2-, -NH-CH2-G2-, -N (alquilo inferior) -CH2-G2- o -CH2-G2-, [en donde G2 se une a R2, G2-R2 es enlace-R2, fenileno-G3-R2, fenileno-G4-O-R2, fenileno-G5-NH-R2, fenileno-G6-N(alquilo inferior)-R2 o quinolinadiilo-O-R2, el fenileno de los grupos que contienen fenileno está opcionalmente sustituido con uno o más sustituyentes; G3-R2 es -O-alquileno inferior-R2, o similar, G4-O- es alquileno inferior-O-, o similar; G5 es alquileno inferior y G6 es alquileno inferior.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29963110P | 2010-01-29 | 2010-01-29 | |
| US35972910P | 2010-06-29 | 2010-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6561817A2 true CO6561817A2 (es) | 2012-11-15 |
Family
ID=43797869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12121461A CO6561817A2 (es) | 2010-01-29 | 2012-07-19 | Derivados de piridina di-sustituida como agentes anticancer |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8722663B2 (es) |
| EP (1) | EP2528897B9 (es) |
| JP (1) | JP5335932B2 (es) |
| KR (1) | KR101411030B1 (es) |
| CN (1) | CN102791690B (es) |
| AR (1) | AR080057A1 (es) |
| AU (1) | AU2011211306B2 (es) |
| CA (1) | CA2788073A1 (es) |
| CO (1) | CO6561817A2 (es) |
| DK (1) | DK2528897T3 (es) |
| EA (1) | EA026042B1 (es) |
| ES (1) | ES2521016T3 (es) |
| HK (1) | HK1178523A1 (es) |
| HR (1) | HRP20141190T1 (es) |
| IL (1) | IL221146A (es) |
| MX (1) | MX2012008391A (es) |
| MY (1) | MY160875A (es) |
| NZ (1) | NZ601794A (es) |
| PL (1) | PL2528897T3 (es) |
| PT (1) | PT2528897E (es) |
| RS (1) | RS53705B1 (es) |
| SG (1) | SG182663A1 (es) |
| SI (1) | SI2528897T1 (es) |
| SM (1) | SMT201500007B (es) |
| TW (1) | TWI404713B (es) |
| UA (1) | UA107692C2 (es) |
| WO (1) | WO2011093524A1 (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013047223A (ja) * | 2011-07-28 | 2013-03-07 | Otsuka Pharmaceut Co Ltd | 医薬 |
| KR102334260B1 (ko) | 2013-03-14 | 2021-12-02 | 스미토모 다이니폰 파마 온콜로지, 인크. | Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법 |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| EP3036222A2 (en) * | 2013-08-23 | 2016-06-29 | Virginia Commonwealth University | Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| WO2016049524A1 (en) * | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| BR112017021869A2 (pt) | 2015-04-10 | 2018-12-11 | Araxes Pharma Llc | compostos quinazolina substituídos e métodos de uso dos mesmos |
| EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| JP2018533939A (ja) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Ｒａｓの阻害剤をスクリーニングするための方法 |
| CN108779097A (zh) | 2015-11-16 | 2018-11-09 | 亚瑞克西斯制药公司 | 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法 |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| CN110036010A (zh) | 2016-09-29 | 2019-07-19 | 亚瑞克西斯制药公司 | Kras g12c突变蛋白的抑制剂 |
| JP2019534260A (ja) | 2016-10-07 | 2019-11-28 | アラクセス ファーマ エルエルシー | Ｒａｓの阻害剤としての複素環式化合物およびその使用方法 |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| EP3630746A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| EP3630745A2 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Covalent inhibitors of kras |
| BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
| EP3826684A4 (en) | 2018-07-26 | 2022-04-06 | Sumitomo Dainippon Pharma Oncology, Inc. | METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE THEREOF |
| CN112812781B (zh) * | 2021-01-21 | 2023-09-29 | 西安瑞联新材料股份有限公司 | 一种基于双哌嗪类苯并噁唑液晶化合物及其制备方法 |
| CN116903587B (zh) * | 2023-06-01 | 2024-03-22 | 三峡大学 | 一种角鲨烯环氧酶抑制剂及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63301880A (ja) * | 1985-09-03 | 1988-12-08 | Otsuka Pharmaceut Co Ltd | ５−フルオロウラシル誘導体 |
| AR015733A1 (es) * | 1998-03-25 | 2001-05-16 | Otsuka Pharma Co Ltd | DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO. |
| US6262088B1 (en) * | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| JP2001089450A (ja) * | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ピリジン誘導体含有医薬製剤 |
| JP2001089412A (ja) * | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
| JP2002226429A (ja) * | 2001-02-06 | 2002-08-14 | Fuji Photo Film Co Ltd | アクリル酸エステル化合物の製造方法 |
| GB0224917D0 (en) * | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
| RU2416608C2 (ru) * | 2004-08-06 | 2011-04-20 | Оцука Фармасьютикал Ко., Лтд. | Ароматическое соединение |
| JP5142513B2 (ja) * | 2005-12-05 | 2013-02-13 | 大塚製薬株式会社 | 医薬 |
| SI1957073T1 (sl) | 2005-12-05 | 2014-08-29 | Otsuka Pharmaceutical Co., Ltd. A Corporation Organized Under The Laws Of Japan | Medicinsko zdravilo |
| UA95978C2 (ru) * | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
| US20100136509A1 (en) | 2007-07-02 | 2010-06-03 | Alden Mejer | System and method for clinical trial investigator meeting delivery and training including dynamic media enrichment |
| TWI440638B (zh) | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
| DE202009007345U1 (de) * | 2009-05-22 | 2009-09-10 | Schebo (R) . Biotech Ag | Neue Pharmazeutika und Arzneimittelzubereitungen |
-
2011
- 2011-01-28 KR KR1020117025212A patent/KR101411030B1/ko not_active IP Right Cessation
- 2011-01-28 PL PL11705048T patent/PL2528897T3/pl unknown
- 2011-01-28 SG SG2012054243A patent/SG182663A1/en unknown
- 2011-01-28 DK DK11705048.4T patent/DK2528897T3/en active
- 2011-01-28 CN CN201180007162.2A patent/CN102791690B/zh not_active Expired - Fee Related
- 2011-01-28 NZ NZ601794A patent/NZ601794A/en not_active IP Right Cessation
- 2011-01-28 WO PCT/JP2011/052302 patent/WO2011093524A1/en active Application Filing
- 2011-01-28 AU AU2011211306A patent/AU2011211306B2/en not_active Ceased
- 2011-01-28 US US13/318,053 patent/US8722663B2/en not_active Expired - Fee Related
- 2011-01-28 JP JP2011545133A patent/JP5335932B2/ja not_active Expired - Fee Related
- 2011-01-28 ES ES11705048.4T patent/ES2521016T3/es active Active
- 2011-01-28 MX MX2012008391A patent/MX2012008391A/es active IP Right Grant
- 2011-01-28 EP EP11705048.4A patent/EP2528897B9/en active Active
- 2011-01-28 SI SI201130359T patent/SI2528897T1/sl unknown
- 2011-01-28 EA EA201290720A patent/EA026042B1/ru not_active IP Right Cessation
- 2011-01-28 RS RS20140688A patent/RS53705B1/en unknown
- 2011-01-28 CA CA2788073A patent/CA2788073A1/en not_active Abandoned
- 2011-01-28 AR ARP110100297A patent/AR080057A1/es unknown
- 2011-01-28 TW TW100103410A patent/TWI404713B/zh not_active IP Right Cessation
- 2011-01-28 MY MYPI2012003367A patent/MY160875A/en unknown
- 2011-01-28 UA UAA201209216A patent/UA107692C2/uk unknown
- 2011-01-28 PT PT117050484T patent/PT2528897E/pt unknown
-
2012
- 2012-07-19 CO CO12121461A patent/CO6561817A2/es unknown
- 2012-07-26 IL IL221146A patent/IL221146A/en not_active IP Right Cessation
-
2013
- 2013-05-06 HK HK13105398.2A patent/HK1178523A1/xx not_active IP Right Cessation
-
2014
- 2014-12-09 HR HRP20141190AT patent/HRP20141190T1/hr unknown
-
2015
- 2015-01-09 SM SM201500007T patent/SMT201500007B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6561817A2 (es) | Derivados de piridina di-sustituida como agentes anticancer | |
| CL2017002350A1 (es) | Silanos y composiciones curables que contienen dichos silanos como reticulantes | |
| TR201900038T4 (tr) | GPR6'nın tetrahidropiridopirazin modülatörleri. | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| PE20160122A1 (es) | Compuestos nobles y composiciones para la inhibicion de fasn | |
| CR20130501A (es) | Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos | |
| MY169043A (en) | New dihydroquinoline-2-one derivatives | |
| CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| UY31232A1 (es) | Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones | |
| BR112013018732A2 (pt) | novos derivados de amida de aril-benzocicloalquila | |
| TR201906413T4 (tr) | Bir makrosiklik hcv ns3 inhibe edici tripeptidin sentezi. | |
| MY169267A (en) | New aryl-quinoline derivatives | |
| MY161134A (en) | Piperazine compound having a pgds inhibitory effect | |
| AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| CR20160082A (es) | Nuevo derivado de triazina | |
| CO6481003A2 (es) | Compuesto de benzazepina | |
| PH12014502108A1 (en) | Polyamide compositions with improved optical properties | |
| IN2014DN08653A (es) | ||
| AR085770A1 (es) | Compuestos antibioticos derivados de homoeritromicina y composiciones farmaceuticas | |
| CO6660459A2 (es) | Derivados de 4-(metilaminofenoxi)piridin-3-il-benzamina para tratar cancer | |
| PH12014502845B1 (en) | Novel cholecystokinin receptor ligands | |
| IN2015DN02514A (es) | ||
| SA515360302B1 (ar) | مركبات رباعي أكسا ثنائي فوسفا سبيرو | |
| CY1115784T1 (el) | Παραγωγα δι-υποκατεστημενης πυριδινης ως αντικαρκινικα | |
| CR20130029A (es) | Compuestos de tiofeno 2,3,5-trisustituidos y usos de los mismos |